The FREE webinar, Lactobacillus: What Brands Need to Know About the Taxonomic Changes, will take place on December 11 at 12:30pm Eastern/ 9:30am Pacific.
Big changes are coming to how many of the most popular – and commercially important – probiotics are classified. The name Lactobacillus is instantly recognizable to many consumers and healthcare professionals, but the genus is extremely diverse and includes 251 species. Scientists have been working for years on this reclassification, and we’re close to a final list being published.
These changes will have significant impacts on many areas, from labeling to scientific publications and IP.
In this webinar, NutraIngredients-USA has assembled a panel of experts to talk about the scientific rationale, the commercial and legal implications, and what brands need to know about the impending changes.
Attendees will also have the opportunity to ask a burning question about this topic in advance by submitting the question when they register. For more information and to register, please click HERE.
Our expert speakers include:
Dr Elisa Salvetti, Consultant in Agro-Food Microbiology and a member of the international reclassification project team
Ivan Wasserman, Managing Partner, Amin Talati Wasserman
George Paraskevakos, Executive Director of the International Probiotics Association
Dr Jessica ter Haar, Director of Scientific Affairs, International Probiotics Association
Ewa Hudson, Director of Insights, Lumina Intelligence
The event is sponsored by:
LactoSpore: Sabinsa’s shelf-stable probiotic Bacillus coagulans MTCC 5856 is known worldwide as LactoSpore. The health benefits and stability of LactoSpore have been published in multiple peer-reviewed journals.
Atlantia Food Clinical Trials: A world class company that performs acute, observational and intervention studies to ICH-GCP standards for the functional foods and beverages, supplements, pre- and probiotics and microbiome-based therapeutics sectors.
ADM-Biopolis: Leaders in the scale-up and industrial manufacturing of probiotics, developing novel, proprietary and tailored strains for skin health, gastrointestinal health, immune health, oral health, and more every year that go through extensive pre-clinical and initial clinical evaluation.